Leerink Partners stays Outperform on Ovid Therapeutics Inc (OVID): Ph2 'solid probability of success'
Tweet Send to a Friend
Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
